Technical Analysis for HOWL - Werewolf Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Crossed Above 20 DMA | Bullish | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Up 3 Days in a Row | Strength | 0.00% | |
20 DMA Resistance | Bearish | 4.10% | |
Pocket Pivot | Bullish Swing Setup | 4.10% | |
Lower Bollinger Band Walk | Weakness | 4.10% | |
Wide Bands | Range Expansion | 4.10% | |
Slingshot Bearish | Bearish Swing Setup | 6.38% | |
Lower Bollinger Band Walk | Weakness | 6.38% | |
Wide Bands | Range Expansion | 6.38% |
Alert | Time |
---|---|
60 Minute Opening Range Breakout | about 16 hours ago |
Up 5% | about 16 hours ago |
Rose Above 20 DMA | about 16 hours ago |
Rose Above Previous Day's High | about 16 hours ago |
5x Volume Pace | about 16 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/08/2024
Werewolf Therapeutics, Inc. Description
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It offers PREDATOR, a platform of protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. It also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Solid Tumors Health Sciences Treatment Of Cancer Cancer Immunotherapy Lymphoma Hematologic Malignancies Advanced Solid Tumors Metastatic Solid Tumors
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 8.1939 |
52 Week Low | 1.5735 |
Average Volume | 203,517 |
200-Day Moving Average | 3.82 |
50-Day Moving Average | 6.28 |
20-Day Moving Average | 5.80 |
10-Day Moving Average | 5.46 |
Average True Range | 0.48 |
RSI (14) | 50.25 |
ADX | 18.08 |
+DI | 21.88 |
-DI | 23.31 |
Chandelier Exit (Long, 3 ATRs) | 5.31 |
Chandelier Exit (Short, 3 ATRs) | 5.93 |
Upper Bollinger Bands | 6.71 |
Lower Bollinger Band | 4.90 |
Percent B (%b) | 0.52 |
BandWidth | 31.17 |
MACD Line | -0.22 |
MACD Signal Line | -0.20 |
MACD Histogram | -0.0148 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 6.58 | ||||
Resistance 3 (R3) | 6.56 | 6.30 | 6.45 | ||
Resistance 2 (R2) | 6.30 | 6.11 | 6.31 | 6.41 | |
Resistance 1 (R1) | 6.07 | 6.00 | 6.19 | 6.09 | 6.37 |
Pivot Point | 5.81 | 5.81 | 5.87 | 5.82 | 5.81 |
Support 1 (S1) | 5.58 | 5.62 | 5.70 | 5.60 | 5.31 |
Support 2 (S2) | 5.32 | 5.51 | 5.33 | 5.27 | |
Support 3 (S3) | 5.09 | 5.32 | 5.23 | ||
Support 4 (S4) | 5.11 |